Brokerages expect Agenus Inc. (NASDAQ:AGEN) to announce earnings of ($0.36) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Agenus’ earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.37). Agenus reported earnings of ($0.24) per share in the same quarter last year, which would indicate a negative year over year growth rate of 50%. The business is scheduled to issue its next quarterly earnings report before the market opens on Thursday, August 3rd.
On average, analysts expect that Agenus will report full-year earnings of ($1.14) per share for the current fiscal year. For the next year, analysts anticipate that the business will report earnings of ($1.37) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that follow Agenus.
Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.14. Agenus had a negative net margin of 257.79% and a negative return on equity of 37,577.49%. The company had revenue of $26.96 million during the quarter, compared to analysts’ expectations of $5.22 million.
Several equities research analysts recently weighed in on AGEN shares. Maxim Group restated a “buy” rating and issued a $7.00 price target on shares of Agenus in a research report on Sunday, April 23rd. HC Wainwright set a $5.00 price target on shares of Agenus and gave the stock a “hold” rating in a research report on Saturday, May 6th. Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Wednesday, July 5th. ValuEngine cut shares of Agenus from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 8th. Finally, BidaskClub upgraded shares of Agenus from a “hold” rating to a “buy” rating in a research report on Monday, July 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Agenus currently has an average rating of “Buy” and a consensus target price of $5.88.
Large investors have recently made changes to their positions in the company. Chicago Equity Partners LLC boosted its stake in shares of Agenus by 42.6% in the first quarter. Chicago Equity Partners LLC now owns 454,830 shares of the biotechnology company’s stock valued at $1,715,000 after buying an additional 135,950 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Agenus by 1.9% in the first quarter. Wells Fargo & Company MN now owns 466,799 shares of the biotechnology company’s stock valued at $1,759,000 after buying an additional 8,921 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Agenus by 175.7% in the first quarter. SG Americas Securities LLC now owns 37,171 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 23,689 shares in the last quarter. State Street Corp boosted its stake in shares of Agenus by 64.3% in the fourth quarter. State Street Corp now owns 3,502,274 shares of the biotechnology company’s stock valued at $14,430,000 after buying an additional 1,370,515 shares in the last quarter. Finally, Neuberger Berman Group LLC purchased a new position in Agenus during the first quarter worth $273,000. Institutional investors own 42.61% of the company’s stock.
Shares of Agenus (NASDAQ:AGEN) traded down 0.112% during midday trading on Monday, hitting $4.475. 956,599 shares of the stock were exchanged. The firm has a 50-day moving average of $4.20 and a 200-day moving average of $3.90. Agenus has a 1-year low of $3.20 and a 1-year high of $7.49. The company’s market capitalization is $443.55 million.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with our FREE daily email newsletter.